Growth Strong, Margins Pinched—Execution Will Decide

Tempsens delivered headline growth numbers—33% revenue to ₹118.7 crore, 16% net profit to ₹16.3 crore—that should reassure. But the gap between the two tells the real story. Revenue expanded more than double the pace of profit, a direct result of EBITDA margin compression: 22.4% in Q1 versus 25.3% a year ago, a 330 basis point slide. Management is explicit about the cause: a 45% surge in employee costs (to ₹20.4 crore, including 83 new R&D engineers and ESOP charges) that cut 140 bps from the bottom line. The bet, stated clearly on the call, is that this headcount investment will be absorbed into revenue growth by the second half of the year, recovering margins. The market, having given the stock a +0.18% pop on day 1, then faded it 2.53% by day 3, is not yet convinced.

Three shifts define Q1 against the prior year backdrop: Export mix accelerated to 34% of revenue (from 25%), with export revenue growing 78% to INR 39.8 crore—management is targeting 35%+ by year-end and the order book sits ~80% export-heavy. OEM business is reshaping the revenue model; management flagged that OEM sales will exceed 50% of total revenue by FY28, up from ~33% today, anchored by Micro-Epsilon (temperature sensors JV) and Victura (5-year automotive supply deal, INR 120 Cr peak potential). Capex roadmap expanded dramatically: 4 concurrent projects (EDGE pyromters, Units 6/8 cable/heater plants, brownfield OEM facility) launching Q4 FY27–Q3 FY28 with INR 500 crore aggregate peak revenue potential—versus INR 445 crore base revenue in FY26. Each represents execution risk; together they represent a strategic pivot toward higher-margin, less commodity-exposed revenue and away from India-centric exposure.

The result announcement on Wed Sep 16 sparked a modest +0.18% pop from the ₹540.55 close, but by day 3 the stock had faded to down 2.53%—a ~₹14 crore market-cap washout from the intraday high. The fade suggests traders are unconvinced by one or both of: (1) the pace of margin recovery (management guided H2 FY27 for partial recovery, full recovery H2 FY28), or (2) the capex execution timeline on 4 concurrent projects, one of which (heating facility) already slipped into Q1. Bulk block deals in the prior two weeks show institutional positioning at ₹567–593 per share; matched buys/sells by JUNOMONETA on Sep 09 near ₹593 look like hedging or rebalancing rather than conviction buying. No clear promoter or insider-linked selling near the highs.